Bioequivalence Study of Fosinopril 40mg Tablets Under Fasting Conditions
Completed
Ranbaxy Laboratories Limited
N/A
2002-10-01
The objective of this study is to compare the relative bioavailability of fosinopril sodium
40 mg tablets (Ranbaxy Laboratories Limited, Lot No. 1238312) with that of Monopril® in
healthy adult subjects under fasting conditions.
Bioequivalence Study of Fosinopril 40mg Tablets Under Fed Conditions
Completed
Ranbaxy Laboratories Limited
N/A
2002-10-01
The objective of this study is to compare the relative bioavailability of fosinopril sodium
40 mg tablets (Ranbaxy Laboratories Limited, Lot No. 1238312) with that of Monopril® in
healthy adult subjects under non-fasting conditions.
Bioequivalence Study of Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fasting Conditions
Completed
Ranbaxy Laboratories Limited
N/A
2003-03-01
The objective of this study was to compare the relative bioavailability of Fosinopril sodium
and hydrochlorothiazide 20-12.5 mg tablets by Ranbaxy Laboratories Limited with that of
Monopril ®.-HCT 20-12.5 mg tablets by Bristol-Meyers Squibb following a single oral dose (1 x
20-12.5 mg tablet) in healthy adult subjects under fasting conditions
Bioequivalence Study of Fosinopril Sodium / Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fed Conditions
Completed
Ranbaxy Laboratories Limited
N/A
2003-03-01
The objective of this study is to compare the relative bioavailability of Fosinopril sodium
and hydrochlorothiazide 20-12.5 mg tablets of Ranbaxy laboratories Limited with that of
Monopril ® - HCT 20-12.5 mg tablets by Bristol Meyers Squibb following a single oral dose (1
x 20/12.5 mg tablet) in healthy adult subjects under non-fasting conditions.
Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension
Unknown status
First Affiliated Hospital of Zhejiang University
Phase 4
2016-02-01
The purpose of this study is to compare the effect of fosinopril plus benidipine vs.
fosinopril plus hydrochlorothiazide on the renal function during the 6-month treatment in CKD
patients with HTN.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
